NFL Biosciences SA: A Focus on Botanical Solutions for Addiction

NFL Biosciences SA, a France-based company listed on the NYSE Euronext Paris, operates within the health care sector, specializing in botanical pharmaceutical services. The company is dedicated to developing innovative solutions to combat addiction, leveraging botanical agents to enhance treatment efficacy.

As of July 21, 2025, NFL Biosciences SA’s close price stood at 1.15 EUR, with a market capitalization of 14,470,000 EUR. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of 2.74 EUR on October 7, 2024, and a low of 1.05 EUR on July 1, 2025. The price-to-earnings ratio is currently at -5.59, reflecting the company’s ongoing investment in research and development.

NFL Biosciences SA is renowned for its flagship product, NFL-101, a patented botanical drug candidate designed to aid smokers in their efforts to quit. This product exemplifies the company’s commitment to using scientific methods to address addiction. NFL-101 aims to increase the likelihood of successful smoking cessation by harnessing the therapeutic potential of botanical compounds.

In addition to its work on smoking cessation, NFL Biosciences SA is expanding its research to address the growing issue of cannabis addiction. The company is applying its scientific approach to develop new drug candidates targeting this emerging challenge, reflecting its broader mission to provide effective, nature-based solutions for addiction treatment.

Overall, NFL Biosciences SA continues to focus on the development and commercialization of botanical pharmaceuticals, positioning itself as a leader in the field of addiction treatment. The company’s innovative approach and commitment to scientific research underscore its potential to make significant contributions to public health.